enGene Therapeutics Inc. (NasdaqCM: ENGN)
Health Care · Biotechnology · CA
$1.63
-6.07% today · -79.1% 1Y
enGene Therapeutics Inc. (NasdaqCM: ENGN) operates in the Biotechnology industry within the Health Care sector. The company is valued at $115.94M and employs 82 people.
Over the last twelve months the share price has lost 79.1%, trading between 1.40 and 12.25.
Tweenvest scores enGene Therapeutics Inc. across four factors: quality 35/100, value 29/100. Its strongest factor is quality.
ENGN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $115.94M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.02
- Dividend yield
- —
- Beta (5Y)
- -0.28
- 52-week high
- $12.25
- 52-week low
- $1.40
- Avg volume (3M)
- —
- Shares outstanding
- 67.02M
- Employees
- 82
- Next earnings
- —
About enGene Therapeutics Inc.
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
- ISIN
- CA29286X1015
- Listed since
- Feb 1, 2022
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Nykode Therapeutics ASOB: NYKD | $117.42M | Nkr3.20 | -6.98% |
| Oncopeptides AB (publ)OM: ONCO | $117.17M | Skr2.96 | +40.74% |
| Heidelberg Pharma AGXTRA: HPHA | $116.82M | €2.23 | -5.11% |
| Coya Therapeutics, Inc.NasdaqCM: COYA | $116.12M | $4.60 | -7.07% |
| 4basebio PLCAIM: 4BB | $115.66M | £5.63 | 0.00% |
| PMV Pharmaceuticals, Inc.NasdaqGS: PMVP | $114.78M | $1.39 | -8.55% |
| Genelux CorporationNasdaqCM: GNLX | $114.72M | $2.52 | -1.56% |
| Unicycive Therapeutics, Inc.NasdaqCM: UNCY | $114.49M | $3.79 | -7.79% |
Figures last refreshed Oct 11, 2026.